Cargando…

Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines

Severe Acute Respiratory Syndrome Coronavirus 2 is a novel strain of human beta-coronavirus that has produced over two million deaths and affected one hundred million individuals worldwide. As all the proposed drugs proved to be unstable, inducing side effects, the need to develop a vaccine crystall...

Descripción completa

Detalles Bibliográficos
Autores principales: Doroftei, Bogdan, Ciobica, Alin, Ilie, Ovidiu-Dumitru, Maftei, Radu, Ilea, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063839/
https://www.ncbi.nlm.nih.gov/pubmed/33804914
http://dx.doi.org/10.3390/diagnostics11040579
_version_ 1783682019636543488
author Doroftei, Bogdan
Ciobica, Alin
Ilie, Ovidiu-Dumitru
Maftei, Radu
Ilea, Ciprian
author_facet Doroftei, Bogdan
Ciobica, Alin
Ilie, Ovidiu-Dumitru
Maftei, Radu
Ilea, Ciprian
author_sort Doroftei, Bogdan
collection PubMed
description Severe Acute Respiratory Syndrome Coronavirus 2 is a novel strain of human beta-coronavirus that has produced over two million deaths and affected one hundred million individuals worldwide. As all the proposed drugs proved to be unstable, inducing side effects, the need to develop a vaccine crystallized in a short time. As a result, we searched the databases for articles in which the authors reported the efficacy and safety of the use of several vaccines vaccines by sex, age group, and frequency of adverse reactions. We identified a total of 19 relevant articles that were discussed throughout this manuscript. We concluded that from all eleven vaccines, three had an efficacy >90% (Pfizer–BioNTech (~95%), Moderna (~94%), and Sputnik V (~92%)) except for Oxford–AstraZeneca (~81%). However, Moderna, Sputnik V, and Oxford–AstraZeneca also alleviate severe adverse reactions, whereas in Pfizer–BioNTech this was not revealed. The remaining five (Convidicea (AD5-nCOV); Johnson & Johnson (Ad26.COV2.S); Sinopharm (BBIBP-CorV); Covaxin (BBV152), and Sinovac (CoronaVac)) were discussed based on their immunogenicity, and safety reported by the recipients since only phases 1 and 2 were conducted without clear evidence published regarding their efficacy. CoviVac and EpiVacCorona have just been approved, which is why no published article could be found. All adverse events reported following the administration of one of the four vaccines ranged from mild to moderate; limited exceptions in which the patients either developed severe forms or died, because most effects were dose-dependent. It can be concluded that aforementioned vaccines are efficient and safe, regardless of age and sex, being well-tolerated by the recipients.
format Online
Article
Text
id pubmed-8063839
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80638392021-04-24 Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines Doroftei, Bogdan Ciobica, Alin Ilie, Ovidiu-Dumitru Maftei, Radu Ilea, Ciprian Diagnostics (Basel) Review Severe Acute Respiratory Syndrome Coronavirus 2 is a novel strain of human beta-coronavirus that has produced over two million deaths and affected one hundred million individuals worldwide. As all the proposed drugs proved to be unstable, inducing side effects, the need to develop a vaccine crystallized in a short time. As a result, we searched the databases for articles in which the authors reported the efficacy and safety of the use of several vaccines vaccines by sex, age group, and frequency of adverse reactions. We identified a total of 19 relevant articles that were discussed throughout this manuscript. We concluded that from all eleven vaccines, three had an efficacy >90% (Pfizer–BioNTech (~95%), Moderna (~94%), and Sputnik V (~92%)) except for Oxford–AstraZeneca (~81%). However, Moderna, Sputnik V, and Oxford–AstraZeneca also alleviate severe adverse reactions, whereas in Pfizer–BioNTech this was not revealed. The remaining five (Convidicea (AD5-nCOV); Johnson & Johnson (Ad26.COV2.S); Sinopharm (BBIBP-CorV); Covaxin (BBV152), and Sinovac (CoronaVac)) were discussed based on their immunogenicity, and safety reported by the recipients since only phases 1 and 2 were conducted without clear evidence published regarding their efficacy. CoviVac and EpiVacCorona have just been approved, which is why no published article could be found. All adverse events reported following the administration of one of the four vaccines ranged from mild to moderate; limited exceptions in which the patients either developed severe forms or died, because most effects were dose-dependent. It can be concluded that aforementioned vaccines are efficient and safe, regardless of age and sex, being well-tolerated by the recipients. MDPI 2021-03-24 /pmc/articles/PMC8063839/ /pubmed/33804914 http://dx.doi.org/10.3390/diagnostics11040579 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
Doroftei, Bogdan
Ciobica, Alin
Ilie, Ovidiu-Dumitru
Maftei, Radu
Ilea, Ciprian
Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
title Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
title_full Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
title_fullStr Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
title_full_unstemmed Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
title_short Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
title_sort mini-review discussing the reliability and efficiency of covid-19 vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063839/
https://www.ncbi.nlm.nih.gov/pubmed/33804914
http://dx.doi.org/10.3390/diagnostics11040579
work_keys_str_mv AT dorofteibogdan minireviewdiscussingthereliabilityandefficiencyofcovid19vaccines
AT ciobicaalin minireviewdiscussingthereliabilityandefficiencyofcovid19vaccines
AT ilieovidiudumitru minireviewdiscussingthereliabilityandefficiencyofcovid19vaccines
AT mafteiradu minireviewdiscussingthereliabilityandefficiencyofcovid19vaccines
AT ileaciprian minireviewdiscussingthereliabilityandefficiencyofcovid19vaccines